A prospective, randomized, open-label, placebo-controlled comparative study of Bacillus coagulans GBI-30,6086 with digestive enzymes in improving indigestion in geriatric population

Kumar, Vaijayanti A.; Sudha, Kulur Mukhyaprana; Bennur, Shilpa; Dhanasekar, Karukkupalayam Ramasamy

doi:10.4103/jfmpc.jfmpc_922_19

Cited by 7 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, probiotics also elevate the absorption of smaller peptides and amino acids by altering the abilities of the epithelium lining and promoting transport (20). The role of Bacillus coagulans, Bacillus subtilis, Lactobacillus acidophilus, and Lactobacillus plantarum in enhancing protein digestion has been well documented (18,(31)(32)(33)(34). Previously, Jager et al (18) documented the ability of probiotics to enhance the digestion of pea proteins.…”

Section: Discussionmentioning

confidence: 99%

Study of amino acids absorption and gut microbiome on consumption of pea protein blended with enzymes-probiotics supplement

Rathi,

Gaonkar,

Dhar

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

The current randomized, double-blind, crossover clinical trial was conducted to evaluate changes in the amino acid absorption and gut microbiota on consumption of pea protein supplemented with an enzymes-probiotics blend (Pepzyme Pro). A total of 15 healthy subjects were instructed to take test (pea protein + Pepzyme Pro) or placebo (pea protein + maltodextrin) for 15 days with a 30-day washout period. Blood samples were analyzed for plasma-free amino acids, insulin, and C-reactive protein (CRP). Additionally, nitrogen levels in urine and feces, along with the composition of gut microbiota, were evaluated. On day 15, the test arm showed a tendency to increase the rate of absorption and total absorption (AUC) of amino acids compared with the placebo arm, though the increase was statistically insignificant. In addition, 15-day test supplementation showed a tendency to reduce Tmax of all the amino acids (statistically insignificant except alanine, p = 0.021 and glycine, p = 0.023) in comparison with the placebo supplementation. There were no changes in urine and fecal nitrogen levels as well as serum CRP levels in the test and placebo arm. The increase in serum insulin level after 4 h was statistically significant in both arms, whereas the insulin level of the placebo and test arm at 4 h was not statistically different. Supplementation showed changes with respect to Archaea and few uncharacterized species but did not show statistically significant variations in microbiome profile at the higher taxonomic levels. A study with large sample size and detailed gut microbiome analysis is warranted to confirm the results statistically as well as to characterize altered species. However, the current study could provide an inkling of a positive alteration in protein digestibility, amino acid absorption, and gut microbiome with regular consumption of protein and enzymes-probiotics blend.Clinical Trial Registration:clinicaltrials.gov/; identifier [CTRI/2021/10/037072].

show abstract

Section: Discussionmentioning

confidence: 99%

Study of amino acids absorption and gut microbiome on consumption of pea protein blended with enzymes-probiotics supplement

Rathi,

Gaonkar,

Dhar

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…Co-administration of W. coagulans with protein is a good choice to maximize the health benefits associated with protein supplementation. In an open-label, randomized, prospective study, 5-day treatment with W. coagulans GBI-30, 6086 along with digestive enzymes (amylase, pepsin, and lipase) improved indigestion, abdominal pain, and flatulence in geriatric patients [108].…”

Section: Evidence Of Clinical Research On Improving Gut Healthmentioning

confidence: 99%

Weizmannia coagulans: an Ideal Probiotic for Gut Health

Zhang¹,

Li²,

Lee³

et al. 2023

Food Science and Human Wellness

View full text Add to dashboard Cite

Weizmannia coagulans (formerly Bacillus coagulans) is a spore-forming and lactic acid-producing bacterium. It has recently attracted much attention from researchers and food manufacturers due to its probiotic functions and stability in processing and storage. W. coagulans is capable of improving gut health through the regulation of gut microbiota, modulation of immunity, and improving digestibility and metabolism. Spores, germinated cells and metabolites of W. coagulans modulate the gut micro-environment and further affect other organs. W. coagulans is an environment-friendly probiotic since it can contribute to the host by reconstructing the balance of gut microbiota and only temporarily resides in the intestine after administration. W. coagulans has been generally recognized as safe (GRAS) by the US Food and Drug Administration (FDA), thus it is an ideal probiotic for improving gut health. The merit of its stability in processing and storage provides W. coagulans spores many possibilities for its use in various types of functional food. This review presents an overview of the characteristics of W. coagulans that make it an ideal probiotic candidate and highlights the proposed health benefits with scientific evidence conferred by the administration of W. coagulans.

show abstract

“…While established probiotic strains from the bacterial Lactobacillaceae family and Bifidobacterium genus and fungal strains from the Saccharomyces genus may require protective microencapsulation to survive transit through the GI tract [ 16 , 17 , 18 ], spore-forming Bacillaceae species are generally more resistant to the harsh microenvironments of the GI tract, including acidic gastric pH, intestinal hypoxia, bile salts, and dense colonization by resident microbes [ 19 ]. Commercial probiotic strains of Bacillus subtilis and Heyndrickxia coagulans (formerly Bacillus coagulans ) have been clinically shown to support overall GI tract health and nutrient absorption in healthy adults [ 20 , 21 , 22 , 23 ] and reduce GI symptoms in individuals with mild digestive discomfort [ 20 , 21 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ], dyspepsia [ 31 , 32 ], or inflammatory bowel syndrome [ 33 , 34 , 35 , 36 , 37 ]. Additionally, Alkalihalobacillus clausii (formerly Bacillus clausii ) strains have been demonstrated to modulate immunity in several clinical trials [ 38 , 39 , 40 ].…”

Section: Introductionmentioning

confidence: 99%

Genetic and Phenotypic Characterization of Bacillus velezensis Strain BV379 for Human Probiotic Applications

Brutscher,

Gebrechristos,

Garvey

et al. 2024

Microorganisms

View full text Add to dashboard Cite

Bacterial spore-forming Bacillaceae species, including Bacillus subtilis and Heyndrickxia coagulans, are increasingly utilized for probiotic dietary supplementation. Bacillus velezensis is a Bacillus species that is frequently used as a direct-fed microbial in animal feed but less so as a probiotic for humans. The objective of this study was to characterize the suitability of the Bacillus velezensis strain BV379 for probiotic applications by (1) in silico screening for both adverse genetic elements and putatively beneficial traits, (2) in vitro evaluation of interactions with human intestinal epithelial cells, and (3) in vitro characterization of BV379 spore viability at various temperatures, pH, and in the presence of bile salt. In silico screening of the BV379 genome revealed few genes encoding Bacillaceae-associated toxins, virulence factors, and enzymes involved in the production of toxins. While BV379 encodes five antimicrobial resistance genes, minimum inhibitory concentration assays determined that BV379 is susceptible to all eight clinically relevant antibiotics tested. Preliminary cell culture experiments showed that BV379 lysates did not adversely impact human intestinal epithelial cell viability and monolayer permeability. It was also determined that BV379 spores can easily tolerate the harsh pH, bile salt, and microaerobic conditions typical of the GI tract. Altogether, the results presented herein support the safety and potential of Bacillus velezensis strain BV379 for use as an oral probiotic.

show abstract

A prospective, randomized, open-label, placebo-controlled comparative study of Bacillus coagulans GBI-30,6086 with digestive enzymes in improving indigestion in geriatric population

Cited by 7 publications

References 19 publications

Study of amino acids absorption and gut microbiome on consumption of pea protein blended with enzymes-probiotics supplement

Study of amino acids absorption and gut microbiome on consumption of pea protein blended with enzymes-probiotics supplement

Weizmannia coagulans: an Ideal Probiotic for Gut Health

Genetic and Phenotypic Characterization of Bacillus velezensis Strain BV379 for Human Probiotic Applications

Contact Info

Product

Resources

About